logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Retinal Vein Occlusion Market, By Type (BRVO, CRVO), By Diagnosis (Fundoscopic Examination, Fluorescein Angiography, Optical Coherence Tomography (OCT), and others) opportunities and forecast 2020-2027

  • DLR2221
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Retinal vein occlusion is a blockage of retinal vein owing to blood clot. It is the second most communal cause of graphical impairment worldwide. Blood clot leads to blockage in vein, which starts draining the blood from the retina, resultant in bleeding and swelling, affecting vision of person. Depending on site of blood clot, retinal occlusion is of two major types. Blockage of central vein leads to central retinal vein occlusion (CRVO) and the branch retinal vein occlusion (BRVO) this involves blockage of the smaller branch of veins of retina. Primary causes of vein occlusion are hypertension,, atherosclerosis, and eye conditions such as vitreous hemorrhage and glaucoma.

Rise in the prevalence of eye ailments globally, increase in the geriatric population, surge in the awareness about various eye disorders, enhanced health care infrastructure, scientific advancements, and upcoming new treatments are some of the major drivers of global market. However, side effects allied with the treatment are expected to be a major restraint of the market.

Segment Overview

Based on type, the global market is bifurcated into CRVO and BRVO. The BRVO segment dominated the global market in 2019 and the trend is expected to continue over the forecast period. The growth of segment is accredited to the high prevalence of BRVO as compared to CRVO.

Furthermore, based on condition, the global market can be classified into non-ischemic and ischemic. The non-ischemic section dominated market in 2019 and is likely to continue its domination over the forecast period.

Regional Overview

North America commanded the major market share in 2017 and is expected to capture the significant share over the forecast period. The market in region is projected to grow at rapid pace owing to enhanced health care infrastructure, increase in prevalence of eye diseases, progressive technology, and surge in the geriatric population. Article published by NCBI indicated that CRVO is one of the main causes of unexpected, painless vision loss in the adults. In established countries, occurrence of retinal vein occlusions is about 5.20 per 1000, and the occurrence of CRVO is about 0.8 per 1000. The market in Asia Pacific is expected to increase at high CAGR in the coming years, owing to rise in geriatric population, development in health care infrastructure, and rise in awareness about the eye disorders in the developing countries.

Competitor overview

Major players working in the global market include Sanofi, GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., Bausch & Lomb Incorporated, Bayer AG, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Allergan and Regeneron.

Key Players
  1. GlaxoSmithKline plc,
  2. Sanofi,
  3. Johnson & Johnson Services, Inc.,
  4. AstraZeneca,
  5. Bausch & Lomb Incorporated,
  6. Bristol-Myers Squibb Company,
  7. Bayer AG,
  8. Sun Pharmaceutical Industries Ltd.,
  9. Regeneron,
  10. Allergan.

Market Segmentation

By Type
  • BRVO
  • CRVO
By End User
  • Fundoscopic Examination,
  • Optical Coherence Tomography (OCT),
  • Fluorescein Angiography,
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 15

    2 Market Introduction 19

    • 2.1 Definition 19
    • 2.2 Scope of Study 19
    • 2.3 Research Objective 19
    • 2.4 Assumptions & Limitations 20
      • 2.4.1 Assumptions 20
      • 2.4.2 Limitations 20
    • 2.5 Market Structure 20

    3 Research Methodology 21

    • 3.1.1 Primary Research Methodology 22
    • 3.1.2 Secondary Research Methodology 23
    • 3.1.3 Market Share Analysis 23
    • 3.1.4 Market Pricing Approach 23

    4 Market Dynamics 25

    • 4.1 Introduction 25
    • 4.2 Drivers 26
      • 4.2.1 Increasing prevalence of diabetes and atherosclerosis (Impact Weightage 40%) 26
      • 4.2.2 Change in lifestyle (Impact Weightage 35%) 27
      • 4.2.3 Increasing prevalence of glaucoma, lymphoma, and multiple myeloma (Impact Weightage 25%) 28
    • 4.3 Restraints 29
      • 4.3.1 Side effect of treatment (Impact Weightage 60%) 29
      • 4.3.2 High cost of treatment (Impact Weightage 40%) 30

    5 Market Factor Analysis 31

    • 5.1 Porters Five Forces Model 31
      • 5.1.1 Bargaining Power of Suppliers 32
      • 5.1.2 Bargaining Power of Buyers 32
      • 5.1.3 Threat of New Entrants 32
      • 5.1.4 Threat of Substitutes 32
      • 5.1.5 Intensity of Rivalry 33
    • 5.2 Value Chain Analysis 33
      • 5.2.1 R&D 33
      • 5.2.2 Manufacturing 34
      • 5.2.3 Distribution & Sales 34
      • 5.2.4 Post-sales Monitoring 34
    • 5.3 Demand & Supply: Gap Analysis 35
    • 5.4 Pricing Analysis 35
    • 5.5 Investment Opportunity Analysis 35

    6 Global Retinal Vein Occlusion Market, By Type 36

    • 6.1 Branch Retinal Artery Occlusion 37
    • 6.2 Central Retinal Vein Occlusion 37

    7 Global Retinal Vein Occlusion Market, By Condition 38

    • 7.1 Non-Ischemic 39
    • 7.2 Ischemic 39

    8 Global Retinal Vein Occlusion Market, By Diagnosis 40

    • 8.1 Optical Coherence Tomography 41
    • 8.2 Fundoscopic Examination 41
    • 8.3 Fluorescein Angiography 42

    9 Global Retinal Vein Occlusion Market, By Treatment 43

    • 9.1 Antivascular Endothelial Growth Factor 44
      • 9.1.1 Aflibercept 44
      • 9.1.2 Ranibizumab 45
    • 9.2 Corticosteroid Drugs 45
      • 9.2.1 Triamcinolone Acetonide 46
      • 9.2.2 Dexamethasone 46
    • 9.3 Laser Retinal Photocoagulation 47

    10 Global Retinal Vein Occlusion Market, By End User 48

    • 10.1 Hospitals and Clinics 49
    • 10.2 Research & Academics Centers 49

    11 Global Retinal Vein Occlusion Market, By Region 50

    • 11.1 Americas 50
      • 11.1.1 North America 54
        • 11.1.1.1 U. S. 57
        • 11.1.1.2 Canada 60
      • 11.1.2 South America 63
    • 11.2 Europe 66
      • 11.2.1 Western Europe 70
        • 11.2.1.1 Germany 74
        • 11.2.1.2 France 77
        • 11.2.1.3 U.K 80
        • 11.2.1.4 Italy 83
        • 11.2.1.5 Spain 86
        • 11.2.1.6 Rest of Western Europe 89
      • 11.2.2 Eastern Europe 92
    • 11.3 Asia Pacific 96
      • 11.3.1 Japan 101
      • 11.3.2 China 104
      • 11.3.3 India 107
      • 11.3.4 Australia 110
      • 11.3.5 Republic of Korea 113
      • 11.3.6 Rest of Asia Pacific 116
    • 11.4 Middle East & Africa 120
      • 11.4.1 Africa 128

    12 Competitive Landscape 131

    • 12.1 Introduction 131
    • 12.2 Company Share Analysis 131

    13 Company Profiles 132

    • 13.1 Allergan Plc 132
      • 13.1.1 Company Overview 132
      • 13.1.2 Financials 132
      • 13.1.3 Products 132
      • 13.1.4 Strategy 132
      • 13.1.5 Key Developments 132
    • 13.2 Bayer 133
      • 13.2.1 Company Overview 133
      • 13.2.2 Financials 133
      • 13.2.3 Products 133
      • 13.2.4 Strategy 133
      • 13.2.5 Key Developments 133
    • 13.3 Bristol-Myers Squibb 134
      • 13.3.1 Company Overview 134
      • 13.3.2 Financials 134
      • 13.3.3 Products 134
      • 13.3.4 Strategy 134
      • 13.3.5 Key Developments 134
    • 13.4 Ellex Medical Lasers Ltd. 135
      • 13.4.1 Company Overview 135
      • 13.4.2 Financials 135
      • 13.4.3 Products 135
      • 13.4.4 Strategy 135
      • 13.4.5 Key Developments 135
    • 13.5 GlaxoSmithKline plc 136
      • 13.5.1 Company Overview 136
      • 13.5.2 Financials 136
      • 13.5.3 Products 136
      • 13.5.4 Strategy 136
      • 13.5.5 Key Developments 136
    • 13.6 IRIDEX Corporation 137
      • 13.6.1 Company Overview 137
      • 13.6.2 Financials 137
      • 13.6.3 Products 137
      • 13.6.4 Strategy 137
      • 13.6.5 Key Developments 137
    • 13.7 Lumenis 138
      • 13.7.1 Company Overview 138
      • 13.7.2 Financials 138
      • 13.7.3 Products 138
      • 13.7.4 Strategy 138
      • 13.7.5 Key Developments 138
    • 13.8 Novartis 139
      • 13.8.1 Company Overview 139
      • 13.8.2 Financials 139
      • 13.8.3 Products 139
      • 13.8.4 Strategy 139
      • 13.8.5 Key Developments 139
    • 13.9 NIDEK CO.,LTD. 140
      • 13.9.1 Company Overview 140
      • 13.9.2 Financials 140
      • 13.9.3 Products 140
      • 13.9.4 Strategy 140
      • 13.9.5 Key Developments 140
    • 13.10 Regeneron Pharmaceuticals 141
      • 13.10.1 Company Overview 141
      • 13.10.2 Financials 141
      • 13.10.3 Products 141
      • 13.10.4 Strategy 141
      • 13.10.5 Key Developments 141
    • 13.11 F. Hoffmann-La Roche AG 142
      • 13.11.1 Company Overview 142
      • 13.11.2 Financials 142
      • 13.11.3 Products 142
      • 13.11.4 Strategy 142
      • 13.11.5 Key Developments 142
    • 13.12 Quantel Medical Inc 143
      • 13.12.1 Company Overview 143
      • 13.12.2 Financials 143
      • 13.12.3 Products 143
      • 13.12.4 Strategy 143
      • 13.12.5 Key Developments 143
    • 13.13 Topcon Medical Systems, Inc. 144
      • 13.13.1 Company Overview 144
      • 13.13.2 Financials 144
      • 13.13.3 Products 144
      • 13.13.4 Strategy 144
      • 13.13.5 Key Developments 144
    • 13.14 ZEISS 145
    • 13.14.1 Company Overview 145
    • 13.14.2 Financials 145
    • 13.14.3 Products 145
    • 13.14.4 Strategy 145
    • 13.14.5 Key Developments 145

    14 MRFR Conclusion 146

    • 14.1 Key Findings 146
      • 14.1.1 From CEO’s View Point 146
      • 14.1.2 Unmet Needs 146
    • 14.2 Key companies to watch 146

    15 Appendix 147

    Report You Might be Interested